Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. No good evidence to promote a general use of sevelamer [2]

Kidney International

Volumn 73, Issue 2, 2008, Pages 238-239

  Nguyen, Q V ^a   Descombes, E ^a  

^a Hopital Cantonal de Fribourg   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATE BINDING AGENT; SEVELAMER;

ARTERY CALCIFICATION; DRUG MECHANISM; HEMODIALYSIS PATIENT; HUMAN; LETTER; MORTALITY; PRIORITY JOURNAL; SURVIVAL;

EID: 37549030513     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002667     Document Type: Letter

References (4)

1. Jensen GB, Hampton J. Early termination of drug trials. BMJ 2007; 334: 326.
2. Cardiac Arrhythmia Suppression Trial Investigators. Preliminary results: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-412.
3. Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441.
4. Block GA, Spiegel DM, Elerlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824.